After six years Bellicum admits it’s not ready for prime time
Yet another makeover raises fresh questions over Bellicum’s technology and sees its valuation haemorrhage some more.
A swift big pharma endorsement for Kiadis
Shortly after canning its lead and acquiring the NK cell company Cytosen, Kiadis flips part of the tech to Sanofi.
Allogene and the need for a reliable cell source
A recent technology deal with Notch points to a problem that all allogeneic cell therapy players might sooner or later have to tackle.
Upcoming events – key tests approach for Kadmon and Surface
Kadmon awaits key graft-versus-host disease data, and Surface Oncology's change of tack comes under the spotlight.
Kiadis falls, and Bellicum could be next
EU rejection of Kiadis's stem cell transplant adjunct means that two of three players in this space have been knocked back.
Twilight of the stem cell transplant adjuncts?
The ripples of Molmed’s pivotal study failure could stretch beyond the company’s Zalmoxis product.
Kiadis moves to reduce reliance on its in-house lead
Perhaps sensing trouble ahead Kiadis diversifies beyond ATIR101 by buying Cytosen, but it is a scientific appointment that will cause real excitement.
